

HIV MONITORING QUARTERLY REPORT

FOR ISLAND HEALTH

SECOND QUARTER 2016

















Foreword

As part of the BC Centre for Excellence (BC-CFE) in HIV/AIDS's mandate to evaluate the outcomes of STOP HIV/AIDS programming in BC, we have developed quarterly HIV/AIDS monitoring reports. These reports provide up-to-date data on a variety of key HIV-related surveillance and treatment indicators. Selection of these indicators was achieved through a collaborative process with various Health Authority (HA) representatives. There are six reports in total, one for each HA and one for the province of BC as a whole. In addition, there is a technical report which explains how each HIV indicator is calculated. Data used in these reports come from the British Columbia Centre for Disease Control (BCCDC), MSP billings, hospitalization data from the Discharge Abstract Database, the Sunquest Laboratory database at the Provincial Public Health Microbiology and Reference Laboratory, Providence Health Care laboratory and the BC-CFE Drug Treatment Program (DTP) Database.

The objectives of these reports are to:

- 1. Provide timely HA-specific information on key HIV indicators which will guide and inform HIV leaders and innovators in the development of future HIV interventions and programs which will ultimately lead to decreasing the burden of HIV in BC. The indicators will reflect ongoing or past successful public health interventions and highlight areas in the HIV care spectrum which require further attention and support.
- 2. Highlight limitations in our current data due to incomplete or time lagged data and to develop future strategies to improve complete and timely data capture.

These reports are produced for the benefit of individual HA's. As such, we are enthusiastic about your involvement and cooperation regarding the development of these monitoring reports. Please forward your comments and queries to Irene Day, Director of Operations at the BC-CFE at iday@cfenet.ubc.ca.

List of Indicators

Indicator 1. HIV Testing Episodes

Indicator 2. HIV Testing Rate

Indicator 3. New HIV Diagnoses

Indicator 4. Stage of HIV Infection at Diagnosis

Indicator 5. HIV Cascade of Care

Indicator 6. Programmatic Compliance Score (PCS)

Indicator 7. New Antiretroviral Therapy Starts

Indicator 8. CD4 Cell Count at ART Initiation

Indicator 9. Active and Inactive Drug Treatment Program (DTP) Participants

Indicator 10. Antiretroviral Adherence

Indicator 11. Resistance Testing and Results

Indicator 12. AIDS-Defining Illness

Indicator 13. HIV-Related Mortality

Table of Contents

Acknowledgements and Contributions

BC Provincial STOP Program:

A Note on Monitoring and Interpreting HIV Indicators

Indicator 1	HIV Testing Episodes All HIV Testing Episodes reflect non-prenatal tests. All prenatal tests have been removed.
Figure 1.1	HIV Test Episodes for Island Health, 2011 Q3-2016 Q2
Figure 1.2	HIV Test Episodes for Island Health by Gender, 2011 Q3–2016 Q2
Figure 1.3	HIV Test Episodes for Island Health by Age Category, 2011 Q3-2016 Q2
Figure 1.4	Point-of-Care HIV Tests for Island Health, 2011 Q3-2016 Q2
Figure 1.5	HIV Test Episodes by HSDA for Island Health, 2011 Q3-2016 Q2
Figure 1.6	HIV Test Episodes for Non-Prenatal Females in Island Health by HSDA, 2011 Q3–2016 Q2
Figure 1.7	HIV Test Episodes for Males in Island Health by HSDA, 2011 Q3-2016 Q2
Indicator 2	HIV Testing Rates All HIV Testing Rates reflect non-prenatal tests. All prenatal tests have been removed.
Figure 2.1	Rate of HIV Testing for Island Health and HSDA's, 2009–2015
Figure 2.2	Rate of HIV Testing for Island Health by Gender, 2009–2015
Figure 2.3	Rate of HIV Testing for Island Health by Age Category, 2009–2015
Indicator 3	New HIV Diagnoses
Figure 3.1	New HIV Diagnoses for Island Health, 2011 Q3-2016 Q2
Figure 3.2	New HIV Diagnoses for Island Health by Gender, 2011 Q3-2016 Q2
Figure 3.3	New HIV Diagnoses for Island Health by Age Category, 2011 Q3–2016 Q2
Figure 3.4	New HIV Diagnoses for Island Health by Exposure Category, 2011 Q1–2015 Q2
Figure 3.5	New HIV Diagnoses for Island Health by HSDA, 2011 Q3-2016 Q2
Indicator 4	Stage of HIV Infection at Diagnosis Stage definitions have been altered to remove AIDS diagnosis data. Individuals previously classified as Stage 3 have been re-classified based on CD4 cell count.
Table 1	Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions
Figure 4.1	Stage of HIV Infection at Diagnosis for Island Health, 2011–2015
Figure 4.2	Stage of HIV Infection at Diagnosis for Island Health by Gender, 2011–2015
Figure 4.3	Stage of HIV Infection at Diagnosis for Island Health by Age Category, 2011–2015
Figure 4.4	Stage of HIV Infection at Diagnosis for Island Health by Exposure Category, 2011–2015
Indicator 5	HIV Cascade of Care
Figure 5.1	Estimated Cascade of Care for Island Health, Year Ending 2016 Q2
Figure 5.2	Estimated Cascade of Care for Island Health by Gender, Year Ending 2016 Q2
Figure 5.3	Estimated Cascade of Care for Island Health by Age Category, Year Ending 2016 Q2

Figure 5.4 Estimated Cascade of Care for Island Health by Msm Status, Year Ending 2016 Q2 Figure 5.5 Estimated Cascade of Care for Island Health by Age Category and Msm Status, Year Ending 2016 Q2 Figure 5.6 Estimated Cascade of Care for Island Health by Pwid Status, Year Ending 2016 Q2 Figure 5.7 Estimated Cascade of Care for Island Health by HSDA, Year Ending 2016 Q2 **Indicator 6 Programmatic Compliance Score (PCS)** Table 2 Probability of Mortality, Immunologic Failure and Virologic Failure Based on the Programmatic Compliance Score Figure 6.1 Pcs Components for Island Health, 2014 Q3-2016 Q2 Less than 3 CD4 Tests in First Year Less than 3 Viral Load Tests in First Year Not Having Drug Resistance Testing at Baseline Non-Recommended Antiretroviral Therapy Regimen (ART) Baseline CD4 < 200 cells/ μ L Not Achieving Viral Suppression at 9 Months Figure 6.2 Historical Trends for Pcs Score for Island Health, 2014 Q3-2016 Q2 **Indicator 7** New Antiretroviral Therapy Starts in Island Health Figure 7 BC-CfE Drug Treatment Program Enrollment: New Antiretroviral Participants for Island Health, 2014 Q3-2016 Q2 **Indicator 8 CD4 Cell Count at ART Initiation** Figure 8 CD4 Cell Count at ART Initiation for Island Health, 2014 Q3-2016 Q2 **Indicator 9** Active and Inactive Drug Treatment Program (DTP) Participants Table 3 Distribution of People on ART in Island Health, 2016 Q2 Figure 9 Active and Inactive DTP Participants for Island Health, 2014 Q3–2016 Q2 Indicator 10 **Antiretroviral Adherence** Figure 10 Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for Island Health, 2014 Q3-2016 Q2 Indicator 11 **Resistance Testing and Results** Cumulative Resistance Testing Results by Resistance Category Figure 11 for Island Health, 2014 Q3-2016 Q2 **Indicator 12 AIDs-Defining Illness** Figure 12 AIDS Case Rate and Reports for Island Health, 2008-2015 Indicator 13 **HIV-Related Mortality** Figure 13 HIV-Related Deaths by Year for Island Health, 2004–2011

Acknowledgements and Contributions



British Columbia Centre for Excellence in HIV/AIDS (BC-CFE): The BC-CFE is responsible for the conception, preparation and ongoing review of this quarterly report. The BC-CFE provides the data and outputs for Indicators 5 (HIV Cascade of Care), 6 (Programmatic Compliance Score), 7 (New Antiretroviral Starts), 8 (CD4 Cell Count at ART Initiation), 9 (Active and Inactive Drug Treatment Program Participants), 10 (Antiretroviral Adherence Level), 11 (Resistance Testing Results by Resistance Category), 12 (AIDS-Defining Illness), and 13 (HIV-Related Mortality). The BC-CFE database provides PVL and CD4 cell count testing data, as well as ART use. All PVL measurements in BC are performed at the St Paul's Hospital virology laboratory, thus PVL data capture is 100%. An estimated 80% of all CD4 count measurements performed in the province are captured in the BC-CFE data holdings. The STOP HIV/AIDS Technical Monitoring Committee—BC-CFE is responsible for oversight of the monitoring report. James Nakagawa is responsible for compiling and publishing this report. Lilith Swetland is the editor of this report. Paul Sereda, Dr. Viviane Lima and Nada Gataric perform analysis of Indicators 5–13. This report was conceived and guided by Dr. Julio Montaner.



British Columbia Centre for Disease Control (BCCDC): The BCCDC provides the data and outputs for Indicator 1 (HIV Testing Episodes), Indicator 2 (HIV Testing Rate), Indicator 3 (New HIV Diagnoses), Indicator 4 (Stage of HIV at Diagnosis) and Indicator 12 (AIDS-Defining Illness). The BCCDC is the single provincial agency that centralizes all HIV surveillance through the Public Health Microbiology and Reference Laboratory, which does more than 90% of all HIV screening tests in BC and all confirmatory testing. Olga Mazo, Theodora Consolacion and Dr. Jason Wong are responsible for outputs for Indicators 1–4.

Other Data Sources:

The above databases were supplemented with:

- (I) The BC Vital Statistics database which was used to calculate Indicator 5. The HIV Cascade of Care and Indicator 13. HIV-Related Mortality.
- (II) Linkage and preparation of the de-identified individual-level database used for calculating Indicator 5. The HIV Cascade of Care was facilitated by the British Columbia Ministry of Health.
- (III) The Statistics Canada database: BC and HIV-positive population counts were acquired through the statistics Canada website to calculate HIV-specific mortality rates for Indicator 13. HIV-Related Mortality.

Membership of the STOP HIV/AIDS Technical Monitoring Committee-BC-CfE

Dr. Rolando Barrios, Chair, BC-CFE

Dr. Kate Heath, BC-CFE

Dr. Bohdan Nosyk, BC-CFE

Dr. Viviane Dias Lima, BC-CFE

Irene Day, BC-CFE

Dr. Jean Shoveller, BC-CFE

Dr. Jason Wong, BCCDC

Dr. Mel Krajden, BCCDC

Salman Klar, FHA

Jennifer May-Hadford, іна

Kari Harder, NHA

Dr. Neora Pick, PHSA

Dr. Reka Gustafson, vсна

Dr. Melanie Rusch, vіна

The Seek and Treat for Optimal Prevention (STOP) HIV/AIDS BC Provincial Program: A Note on Monitoring and Interpreting HIV Indicators

The Seek and Treat for Optimal Prevention (STOP) of HIV/AIDS programme is a provincial initiative to improve HIV diagnosis and care delivery in BC through increased HIV-specific funding to all Health Service Delivery Areas (HSDA'S) across BC. The STOP provincial programme is an expansion of a four-year STOP pilot project which was implemented in two Health Service Delivery Areas in March 2010; the Vancouver HSDA which bears the largest burden of the HIV epidemic in the province and the Northern Interior HSDA which bears a high burden of HIV-related mortality. The STOP pilot project demonstrated the urgent need for improved efforts in early diagnosis of HIV and timely initiation of antiretroviral therapy (ART) initiation.

The expansion to a province-wide programme was announced on November 30th, 2013 by the BC Ministry of Health with roll out of funding beginning on April 1st, 2013. This funding is intended to be used in the implementation and evaluation of HIV-related diagnosis and care initiatives within individual HA's. Goals of the project include: 1. A reduction in the number of new HIV infections in BC; 2. Improvements in the quality, effectiveness, and reach of HIV prevention services; 3. An increase in early diagnosis of HIV; 4. A reduction in AIDS cases and HIV-related mortality.

The goals of HA-led STOP-funded initiatives are to work toward achieving these goals. To these ends some outcome measures or indicators of progress have been drafted that should be considered in the design and implementation phases of these initiatives.

HIV Testing Episodes and Rates

In this section, the number of HIV test episodes and point of care (POC) HIV tests conducted each quarter in BC is shown. In general terms the goal is to increase the number of tests performed and to maximize testing efficiency. Test episodes are allocated by region according to where the test is performed.

Indicator 1. HIV Testing Episodes

Figure 1.1 HIV Test Episodes for Island Health




Figure 1.2 HIV Test Episodes by Gender for Island Health 1,2




Figure 1.3 HIV Test Episodes by Age Category for Island Health 1,2 2.4 -2.2 2.0 -1.8 # HIV Test Episodes (thousands) 1.6 < 30 1.4 1.2 -1.0 0.8 -≥ 50 0.6 40-49

0.4 Q3 Q4 Q2 Q2 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q3 Q4 Q1 Q3 2011 2012 2013 2014 2015 2016 < 30 1.5 1.6 1.4 1.5 1.5 1.6 1.7 1.6 1.8 1.6 1.7 2.0 1.9 2.3 2.2 30-39 1.2 1.0 0.9 1.0 1.0 0.9 1.1 1.3 1.3 1.3 1.0 1.0 1.1 1.1 40-49 0.6 0.6 0.7 0.7 0.7 0.7 0.7 0.8 0.8 0.9 0.9 1.0 1.0 0.6 0.6



0.8 0.9 1.0 0.8 0.8 0.9 1.0 1.0 1.1 1.4 1.5 1.7

≥ 50



Data Source: The вс Public Health Microbiology and Reference Laboratory (всрнмкі) courtesy of the BC Centre for Disease Control (BCCDC). HIV screening tests conducted by the VIHA Laboratory are not included.

Limitation: Repeat tests in individuals who test using various identifiers may not be identified and these individuals may be counted more than once.

2 Testing does not include point of care tests.





Figure 1.6 HIV Test Episodes for Non-prenatal Females in Island Health by HSDA 1,2 2.4 -2.2 -2.0 1.8 -# HIV Test Episodes (thousands) 1.6 -South Vancouver Island 1.4 -1.2 -1.0 -0.8 -Central Vancouver Island 0.6 -0.4 -North Vancouver Island 0.2 -0.0 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q4 Q1 2011 2012 2013 2014 2015 2016 0.7 0.7 0.6 0.5 0.5 0.5 0.6 0.7 0.6 0.6 0.7 0.7 1.0 1.0 1.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 1.1 1.2 1.2 1.3 1.3 1.3 1.4 1.4 1.4 1.5 1.4 1.5 1.6 1.8 1.9 2.0



Indicator 2. HIV Testing Rates

Figure 2.1 Rate of HIV Testing for Island Health and HSDAs ²




Figure 2.2 Rate of HIV Testing by Gender for Island Health ²




Figure 2.3 5400 4800 4200 30-39 HIV Testing Episodes per 100,000 Population 3600 -3000 -< 30 2400 40-49 1800 1200 ≥ 50 600 2009 2010 2011 2012 2013 2014 2015 2445.6 4215.3 2814.1 4725.3 2656.8 3269.4 5553.3 2490.1 2494.4 2381.6 < 30 30-39 3963.9 4042.8 3837.8 4339.5 2216.7 830.9 2193.7 823.9 2354.5 952.2 2617.7 1102.2 2835.5 1260.4 3560.1 1883.7 2239.8 813.8 40-49 ≥ 50

Rate of HIV Testing by Age Category for Island Health $^{\rm 2}$


Testing does not include point of care tests.

New HIV Diagnoses

Trends in HIV diagnoses by gender and exposure category are described. Interpreting HIV diagnoses must be done with consideration that trends are influenced by both changes in testing rate as well as changes in transmission rates. It is important to note that new HIV diagnoses cases and rates are not synonymous with HIV incidence as a person may have become infected with HIV long before they tested positive for HIV. However, as there is no reliable method for measuring HIV incidence, we follow trends in HIV diagnoses.

Indicator 3. New HIV Diagnoses

Figure 3.1 New HIV Diagnoses for Island Health ³ 12 -10 # HIV Diagnoses 8 Q2 Q2 Q2 03 Q4 Q1 Q3 Q4 Q1 Q3 02 Q1 Q4 Q1 Q4 Q1 Q3 Q4 Q3 2014 2011 2012 2013 2015 2016 Island Health 12 10 3 by Provider Address



³ Data Source: BCCDC. When present, "By Provider Address" is graphed as dashed line in same colour.

Figure 3.3 New HIV Diagnoses for Island Health by Age Category ³ # HIV Diagnoses 30-39 ≥ 50 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q1 Q2 Q1 Q2 Q1 2011 2012 2013 2014 2015 2016 < 30 3 30-39 2 3 0 0 0 4 40-49 2 0 5 2 0 3 4 ≥ 50 2

Figure 3.4 New HIV Diagnoses for Island Health by Exposure Category 3.4




Figure 3.5 New HIV Diagnoses for Island Health by HSDA ³ 10 -# HIV Diagnoses Central Vancouver Island South Vancouver Island 6 4 2 North Vancouver Island Q2 Q3 Q4 Q1 Q1 Q2 Q3 Q2 Q1 Q3 Q4 Q1 Q3 Q2 Q3 2011 2012 2013 2014 2015 2016 Central Vancouver Island 3 5 by Provider Address 0 n North Vancouver Island 0 0 0 0 0 0 0 0 0 0 0 by Provider Address 0 0 5 South Vancouver Island 10 by Provider Address

³ Data Source: BCCDC. When present, "By Provider Address" is graphed as dashed line in same colour.

⁴ MSM=men who have sex with men; PWID=people who inject drugs; HET=heterosexual. NIR=No identified risk/exposure.

Stage of HIV Infection at Diagnosis

Classification of stage of HIV infection, in the absence of information regarding recent testing history, is reliant on clinical information available at the time of diagnosis, including first CD4+ cell count and laboratory results suggestive of acute HIV infection (Table 1). The benefits of Treatment as Prevention (TasP) are maximized when antiretroviral therapy (ART) is initiated at high CD4 cell counts. Accordingly, it is preferable that individuals newly diagnosed with HIV be in the early stages of HIV infection (stage o or 1) to allow for early ART initiation.

N.B. Interpretation of Stage of HIV Infection at Diagnosis should proceed with caution. Early increases in diagnosis at late stage (i.e., low CD4 counts) may represent a "catching up" of previously missed long term infected individuals rather than a trend toward diagnosis at later stage of infection.

Indicator 4. Stage of HIV Infection at Diagnosis

Table 1 Staging Classifications of Infection at Time of HIV Diagnosis Based on CDC HIV Surveillance Case Definitions

Stage	Criteria		
0	previous	ńegativ	ria met for acute HIV infection, or ve or indeterminate HIV test within confirmed positive HIV test.
1			CD4 ≥500
2a	Stage 0 not met	and	CD4 350-499
2b			CD4 200-349
3			CD4 <200
Unknown			No available CD4

Updated 2016 Q1: AIDS diagnosis date is no longer used in this indicator.

Figure 4.1 Stage of HIV Infection at Diagnosis for Island Health, 2011–2015 ⁵





Figure 4.2 Stage of HIV Infection at Diagnosis by Gender for Island Health, 2011–2015 ⁵



Data Source: BCCDC

Figure 4.3 Stage of HIV Infection at Diagnosis by Age Category for Island Health, 2011–2015 ⁵





Figure 4.4 Stage of HIV Infection at Diagnosis by Exposure Category for Island Health, 2011–2015 5.6



⁵ Data Source: BCCDC

⁶ MSM=men who have sex with men; PWID=people who inject drugs; HET=heterosexual. NIR=No identified risk/exposure.


HIV Cascade of Care

Indicator 5. HIV Cascade of Care

The success of seek, test, treat and retain (STTR) strategies like STOP is reliant on early diagnosis of HIV, linking newly diagnosed HIV-positive persons with ongoing care, retaining persons in HIV-care; initiating ART based on best evidenced practices and maintaining optimal ART adherence to ensure a suppressed viral load. These stages of HIV-care can be summarized as: 1. HIV diagnosis, 2. Linked to HIV care, 3. Retained in HIV care, 4. On ART, 5. Adherent to ART and 6. Achieving a suppressed VL; collectively, they are referred to as the cascade of care. Attrition between any of these stages of HIV-care means a reduction in the potential of ART as a benefit to the HIV-positive individual and as an HIV transmission prevention method on a population level. Thus, when interpreting trends in the cascade of care, we strive to see increases along each step of the cascade of care (i.e. reduced attrition) with the ultimate goal being 100% within each stage of the cascade. Monitoring the Cascade of Care provides a picture as to where deficiencies lie in the delivery and uptake of HIV-care. In this section we present the cascade of care for the period 2015 Q3–2016 Q2 in Island Health and stratified by sex and age.



Figure 5.2 Estimated Cascade of Care for Island Health by Gender, Year Ending 2016 Q2 7
Men Women



7 Data is for the period 2015 Q3-2016 Q2.


Data Sources:

- i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).
- ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

NB: Transgender have been assigned to their biological sex.

Figure 5.3 Estimated Cascade of Care for Island Health by Age Category, Year Ending 2016 Q2 8




Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

⁸ Data is for the period 2015 Q3-2016 Q2. Data Sources:

i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).






Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

⁹ Data is for the period 2015 Q3-2016 Q2. Data Sources:

i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Figure 5.5 Estimated Cascade of Care for Island Health by Age Category and MSM Status, Year Ending 2016 Q2 ⁹




Data is for the period 2015 Q3–2016 Q2. Data Sources:

Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

i Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).







Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

⁹ Data is for the period 2015 Q3-2016 Q2. Data Sources:

i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).





Limitations: HA assignment is based on the most recent HA of residence of the patient, if not available of the HIV-care provider. If the most recent HA of residence is not updated then the designated HA may be incorrect.

Data is for the period 2015 Q3–2016 Q2.

Data Sources:

i British Columbia Centre for Excellence Drug Treatment Program (DTP) Database (ARV use, VL and CD4 count).

ii Administrative data (ex. MSP billings; hospitalization data from the Discharge Abstract Database (DAD)).

Programmatic Compliance Score

Indicator 6. Programmatic Compliance Score (PCS)

The Programmatic Compliance Score (PCS) is a summary measure of risk of future death, immunologic failure and virologic failure from all causes for people who are starting ART for the first time. It is composed of patient- and physician-driven effects. PCs scores range from o−6 with higher scores indicative of poorer health outcomes and greater risk of death. Table 2 provides mortality, immunologic failure and virologic failure probabilities for given PCs scores. We interpret an individual with a PCS≥4 as being 22 times more likely to die, almost 10 times more likely to have immunologic failure and nearly 4 times as likely to demonstrate virologic failure compared to those individuals with a PCs score of o. A detailed description of how the PCs score is calculated and its validation can be found in the technical report. In short, PCs scores are calculated by summing the results (yes=1, no=0) of six un-weighted non-performance indicators based on IAS−USA treatment guidelines:

- having <3 CD4 cell count tests in the first year after starting antiretroviral therapy (ART);
- 2. having <3 plasma viral load (VL) tests in the first year after starting ART;
- 3. not having drug resistance testing done prior to starting ART;
- 4. starting on a non-recommended ART regimen;
- 5. starting therapy with CD4<200 cells/μL; and
- 6. not achieving viral suppression within 9 months since ART initiation.

In this section we provide PCS scores and their components over time for the province of BC. A decline to 0%, (i.e., all individuals having a score of o) is the eventual goal.

Table 2. Probability of Mortality, Immunologic Failure and Virologic Failure based on the Programmatic Compliance Score

Programmatic Compliance Score	Mortality Risk Ratio (95% Confidence Interval)	Immunologic Failure Risk Ratio (95% CI)	Virologic Failure Risk Ratio (95% CI)
O (Best score)	1 (-)	1 (-)	1 (-)
1	3.81 (1.73-8.42)	1.39 (1.04–1.85)	1.32 (1.05–1.67)
2	7.97 (3.70–17.18)	2.17 (1.54-3.04)	1.86 (1.46–2.38)
3	11.51 (5.28-25.08)	2.93 (1.89-4.54)	2.98 (2.16-4.11)
4 or more (Worst score)	22.37 (10.46–47.84)	9.71 (5.72–16.47)	3.80 (2.52–5.73)

Reference: Lima VD, Le A, Nosyk B, Barrios R, Yip B, et al. (2012) Development and Validation of a Composite Programmatic Assessment Tool for HIV Therapy. PLoS ONE 7(11): e47859. doi:10.1371/journal.pone.0047859

Figure 6.1 $\,$ PCS Components for Island Health, 2014 Q3–2016 Q2 10





Figure 6.2 Historical Trends for PCS Score for Island Health, 2014 Q3-2016 Q2 10,11



Data Source: British Columbia Centre for Excellence Drug Treatment Program (DTP) Database. Limitations: CD4 cell count capture is approximately 80%.


Each quarter's data is calculated as the sum of the 4 quarters leading up to it. e.g. 2013 Q1 is calculated from 2012 Q2 – 2013 Q1. NB: A score of 0 is the best score and a score of 4 or more is the worst score.

Antiretroviral Uptake

In this section we present trends in ART uptake, the number and proportion of new HIV treatment initiations and the number of active and inactive DTP participants. Trends in ART uptake should be interpreted under the consideration of changing BC HIV treatment guidelines. BC HIV treatment guidelines are updated regularly by the BC-CFE Therapeutic Guidelines Committee and reflect those of the International AIDS Society. Most recent changes were made in 2012 and HIV treatment is now recommended for all HIV-positive adults regardless of CD4 cell count; as evidence demonstrates that early initiation of HIV treatment maximizes both the individual's health outcomes as well as the potential of ART as a form of HIV transmission prevention at a population level. As such, trends in the number and proportion of persons on ART and new ART starts (in both naïve and experienced persons) are expected to increase over time at higher CD4 cell counts.


Indicator 7. New Antiretroviral Therapy Starts in Island Health

Figure 7 BC-CfE Drug Treatment Program
Enrollment: New ART Participants in
Island Health, 2014 Q3-2016 Q2 12



Indicator 8. CD4 Cell Count at ART Initiation

Figure 8 CD4 Cell Count at ART Initiation of ART-Naïve DTP Participants in Island Health, 2014 Q3–2016 Q2 ¹³




- 12 Data Source: Drug Treatment Program Database Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.
- 3 Data Source: Drug Treatment Program Database Limitations: CD4 cell count data is approximately 80% complete.

Indicator 9. Active and Inactive DTP Participants

Table 3. Distribution of People on ART for Island Health, 2016 Q2 14

Age	< 30	30
	30-39	97
	40-49	217
	≥ 50	523
Gender	Male	709
	Female	158
Exposure	MSM	255
	PWID	276
Total		867

Figure 9 Active and Inactive DTP Participants for Island Health, 2014 Q3-2016 Q2 15



Definition:

'On antiretroviral therapy' defined as being on treatment in the current quarter

Active DTP participants: An individual who has had medication prescribed at least once in the preceding quarter.

Inactive DTP participants: Persons no longer prescribed drugs through the HIV/AIDS Drug Treatment Program in the last quarter.

Data Source: Drug Treatment Program Database


Limitation: DTP participants are designated to an HA based on most current residence provided by the participant.

Antiretroviral Adherence Level

In this section we present trends in prescription refill adherence levels for individuals in their first year of treatment. Given that the benefits of ART are compromised in the presence of imperfect ART adherence, we expect to see the proportion of persons on ART achieving near perfect adherence (ie. $\geq 95\%$) to increase with time. Furthermore, it is important that trends in the proportion of ART users achieving prescription refill adherence of $\geq 95\%$ keep pace with new ART starts and increase among those continuing on ART.

Indicator 10. Antiretroviral Adherence

Figure 10 Distribution of Individuals by Adherence Level in 1st Year of Therapy, Based on Pharmacy Refill Compliance for Island Health, 2014 Q3–2016 Q2 ¹⁶




¹⁶ Data Source: Drug Treatment Program Database Limitation: Prescription refill adherence is used as a proxy for patient adherence.

Resistance Testing and Results

Indicator 11. Resistance Testing and Results

In this section, we present trends in cumulative resistance testing by resistance category: Suppressed (where a DTP participant's viral load is too low to be genotyped); Wild Type (where no HIV treatment resistances were discovered), Never Genotyped, and Resistances to one, two, three, or four HIV treatment classes. Resistance testing prior to ART initiation is recommended in the BC HIV treatment primary care guidelines. Thus, it is expected that trends over time should find all persons enrolled in the DTP to have been genotyped. Trends over time should also show an increase in the proportion of DTP participants achieving a suppressed status and an increase in resistance testing should not lead to an increase in the number of ART resistances occurring.

Figure 11 Cumulative Resistance Testing Results by Resistance Category for Island Health, 2014 Q3–2016 Q2 ¹⁷




¹⁷ Data Source: Drug Treatment Program Database

Limitation: DTP participants are designated to a HA based on most current residence provided by the participant.

AIDS-Defining Illness

Indicator 12. AIDS-Defining Illness

Improvements in ART and the expansion of ART province-wide has led to very low numbers of recorded AIDS cases across BC. However, interpreting trends in AIDS cases is challenging as AIDS reporting is passive in BC and it is likely that they are under-reported across all Health Authorities. In addition to under-reporting, methods of reporting AIDS cases are inconsistent across HA's and do not truly reflect the current reality of new AIDS diagnoses. Efforts will need to be made to improve under- and inconsistent reporting of AIDS cases across all HA's. The table below shows AIDS cases using three definitions. First, AIDS cases were defined as the number of physician-reported AIDS defining illness (ADI) in a given year. AIDS case reporting is a passive process and physicians can voluntarily report AIDS cases to the BCCDC or DTP. As such, we have plotted both BCCDC reports and DTP reported AIDS cases. We also show the proportion of persons initiating ART with a CD4<200 cells/µL.




Data Source: DTP AIDS cases are obtained from the Drug Treatment Program Database; BCCDC AIDS cases are obtained from the BCCDC; CD4<200 at ART initiation data came from the DTP database.

Limitation: AIDs case reporting was investigated using 3 definitions: First, using AIDs cases reported in AIDs case report forms from the DTP; Second, using AIDs cases reported via the BCCDC and third, using a CD4 cell count of <200 cells/µL at time of ART initiation using DTP data. AIDs case reporting is passive in BC, thus; AIDs case reporting is not well captured. The DTP sends out AIDs reporting forms to physicians annually. The BCCDC uses DTP AIDs case reports as well as physician AIDs case reports made directly to the BCCDC. Interpreting AIDs case reports should be done with these limitations in mind. AIDs data is updated annually as very few AIDs cases reports are reported in general and trends would be difficult to notice if reported quarterly.

HIV-Related Mortality

Indicator 13. HIV-Related Mortality

Evidence indicates that individuals who initiate treatment with recommended ART in a timely fashion may live near normal lifespans. Excess mortality among HIV positive persons is, therefore, an important measure of HIV care with a goal of minimizing HIV-related mortality in British Columbia.



Limitation:

¹⁹ Data Source: BC Vital Statistics

^{1.} DTP participants are designated to an HA based on most current residence provided by the participant.

^{2.} Mortality data is updated annually.

^{3.} The most recent available data was used.

Appendices

	(thousands)	2011 Q3	Q4	2012 Q1	Q2	Q3	Q4	2013 Q1	Q2	Q3	Q4	2014 Q1	Q2	Q3	Q4	2015 Q1	Q2	Q3	Q4	2016 Q1	Q2
Island Hea	alth	3.6	3.5	4.0	3.7	3.8	4.0	4.2	4.5	4.3	4.3	4.9	4.8	4.8	4.9	5.9	6.0	6.4	6.6	7.1	7.2
Gender	Female	1.8	1.7	1.9	1.8	1.9	2.0	2.1	2.2	2.1	2.1	2.3	2.3	2.4	2.4	2.9	3.0	3.2	3.3	3.5	3.7
	Male	1.8	1.7	2.0	1.8	1.8	1.8	2.0	2.1	2.0	1.9	2.2	2.1	2.1	2.1	2.6	2.6	2.8	2.9	3.1	3.2
	Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Age	< 30	1.5	1.5	1.6	1.4	1.5	1.5	1.6	1.7	1.6	1.6	1.8	1.6	1.7	1.8	2.0	1.9	2.0	2.2	2.3	2.2
	30–39	0.9	0.8	1.0	0.9	0.9	1.0	1.0	1.0	1.0	0.9	1.2	1.1	1.1	1.1	1.3	1.3	1.4	1.3	1.5	1.5
	40–49	0.6	0.5	0.6	0.6	0.6	0.6	0.6	0.6	0.6	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.9	0.9	1.0	1.0
	≥ 50	0.6	0.6	0.7	0.7	0.7	0.8	0.9	1.0	0.8	0.8	0.9	1.0	1.0	1.1	1.4	1.5	1.7	1.8	1.9	2.2
POC HIV (not in the		42	12	24	41	90	164	135	200	194	245	347	353	316	325	407	414	371	385	389	328
Central Va	ancouver Islan	d 1.1	1.1	1.2	1.1	1.1	1.1	1.3	1.4	1.3	1.3	1.4	1.6	1.5	1.6	2.0	2.0	2.1	2.1	2.3	2.4
Female		0.5	0.5	0.6	0.5	0.5	0.5	0.6	0.7	0.6	0.6	0.7	0.7	0.7	0.7	1.0	1.0	1.1	1.0	1.1	1.2
Male		0.5	0.6	0.6	0.5	0.6	0.5	0.7	0.6	0.7	0.6	0.7	0.7	0.7	0.7	0.9	1.0	1.0	1.0	1.1	1.1
	ncouver Island	0.2	0.2	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.4	0.4	0.4	0.4	0.4	0.4
Female		0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.2	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.2	
Male		0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2
	ncouver Island	2.3	2.2	2.5	2.4	2.5	2.6	2.6	2.9	2.6	2.7	3.1	2.9	3.0	3.0	3.6	3.7	3.8	4.1	4.3	4.5
Female		1.1	1.1	1.2	1.2	1.3	1.3	1.3	1.4	1.4	1.4	1.5	1.4	1.5	1.6	1.8	1.9	2.0	2.1	2.2	2.3
Male		1.1	1.1	1.3	1.1	1.1	1.2	1.2	1.3	1.2	1.2	1.4	1.3	1.3	1.3	1.5	1.5	1.6	1.7	1.9	2.0
Indicator	2: Rate of HI	V Testing	per 1	00,00																	
	1.1		200			010		2011		201			013		2014		201	_			
Island Hea			1927		191			351.0		1980.		215			35.6		2939.				
	ancouver Islan		1717		174			41.7		1763.		194			68.0		2831.				
	ncouver Island		1343		136			21.1		1050.		117			56.7		1352.				
	ncouver Island		2267		222			67.4		2438.		261			38.4		3531.				
Gender	Female		1911		187			786.1		1963.		218			87.9		3068.				
	Male		1926		194			011.6		1990.		211			73.5		2794.				
Age	< 30		2490		249			881.6		2445.		265			14.1		3269.				
	30-39		3963		404			337.8		4215.		433			25.3		5553.				
	40-49		2216		223			93.7		2354.		261			35.5		3560.				
	≥ 50		830	.9		3.8		323.9		952.		110			60.4		1883.	/		•	_
Indicator	3: New HIV I	diagnasas			2011 Q3)12 Q1 Q	2 Q3	04	2013 Q1		Q3 (201 Q4 Q		Q3		2015 Q1	Q2 ()3 C	201 4 Q1	
Island Hea		By Client		ence	7	7		3 5			9	10		$\frac{1}{6}$ $\frac{2}{4}$		8	3	7	8	6 7	
1014114 1166		By Provide			6	6		3 5			9	10		64		8	3	7	6	5 7	
		ווויייייייייייייייייייייייייייייייייייי	., 21111	~1 C33		1		0 0			1	3		2 1		3	0	2	3	1 0	
Gender		Female			3		/.											/.)
Gender		Female Male			3																
		Male			4	6	4	3 5	12	3	8	7	7	4 3	5	5	3	5	5	5 7	7 9
Gender Age		Male < 30					4 2	3 5 2 1	12	3	8 2	7	7	4 3 1 0	5	5 2	3	5 1	5	5 7 2 3	7 9 3 3
		Male < 30 30–39			4 0 1	6 1 1	4 2 2	3 5 2 1 1 1	2 2	3 1 1	8 2 2	7 2 3	7 1 0	4 3 1 0 1 0	5 0 4	5 2 1	3 0 1	5 1 2	5 3 4	5 7 2 3 0 2	7 9 3 3 2 (
		Male < 30 30–39 40–49			4 0 1 3	6 1 1 1	4 2 2 2	3 5 2 1 1 1 0 1	12225	3 1 1 1	8 2 2 1	7 2 3 4	7 1 0 4	4 3 1 0 1 0 1 2	5 0 4 1	5 2 1 3	3 0 1 1	5 1	5 3 4 1	5 7 2 3 0 2 1 0	7 9 3 3 2 (c) 3 3
Age		Male < 30 30–39 40–49 ≥ 50			4 0 1 3 3	6 1 1	4 2 2 2 0	3 5 2 1 1 1 0 1 0 2	5 12 2 2 5 3	3 1 1 1 1	8 2 2 1 4	7 2 3 4 1	7 1 0 4 2	4 3 1 0 1 0 1 2 3 2	5 0 4 1 2	5 2 1 3 2	3 0 1 1 1	5 1 2 3	5 3 4 1 0	5 7 2 3 0 2 1 0 3 2	7 9 3 3 2 (0) 3
Age		Male < 30 30–39 40–49 ≥ 50 MSM			4 0 1 3 3 3	6 1 1 1 4 1	4 2 2 2 0 2	3 5 2 1 1 1 0 1 0 2 2 4	5 12 2 2 5 3 4 8	3 1 1 1 1 1	8 2 2 1	7 2 3 4 1	7 1 0 4 2 5	4 3 1 0 1 0 1 2 3 2 3 2	5 0 4 1 2	5 2 1 3 2 3	3 0 1 1 1 2	5 1 2 3 1	5 3 4 1 0 2	5 7 2 3 0 2 1 0 3 2 3 -	7 9 3 3 2 (c) 3 3
		Male < 30 30–39 40–49 ≥ 50 MSM PWID			4 0 1 3 3 3 2	6 1 1 1 4 1 0	4 2 2 2 0 2 2	3 5 2 1 1 1 0 1 0 2 2 4 0 0	5 12 2 2 5 3 4 8	3 1 1 1 1 1 0	8 2 2 1 4 4 1	7 2 3 4 1 4 0	7 1 0 4 2 5 0	4 3 1 0 1 0 1 2 3 2 3 2 0 0	5 0 4 1 2 2	5 2 1 3 2 3 3	3 0 1 1 1 2 1	5 1 2 3 1 4	5 3 4 1 0 2 0	5 7 2 3 0 2 1 0 3 2 3 - 0 -	7 9 3 3 2 (c) 3 3
Age		Male < 30 30–39 40–49 ≥ 50 MSM			4 0 1 3 3 3	6 1 1 1 4 1	4 2 2 2 0 2 2	3 5 2 1 1 1 0 1 0 2 2 4	5 12 2 2 5 3 4 8 0 1	3 1 1 1 1 1 0 3	8 2 2 1 4 4	7 2 3 4 1	7 1 0 4 2 5 0	4 3 1 0 1 0 1 2 3 2 3 2 0 0	5 0 4 1 2 2 0 5	5 2 1 3 2 3	3 0 1 1 1 2	5 1 2 3 1 4 1	5 3 4 1 0 2	5 7 2 3 0 2 1 0 3 2 3 -	7 9 3 3 2 (c) 3 3

								2	2011		2012	2			20)13				2014	:			201	5			2	016	
Indicator 3									Q3	Q4	Q1	Q2	Q3	3 Q	4 (Q1 (Q2	Q3	Q4	Q1		Q3	Q4	Q1	l Q	2 (23 (Q4	Q1	Q2
Central Var	ncou	ver		,		it Re			1	3	2				4	2	2	5	3	0	2	1	7			3	4	2	3	1
Island				,		ider 1			0	3	1				4	2	2	5	3	0	1	2	7			2	2	2	3	1
North Vano Island	couve	er				it Re			0	2	1	0			2	0	2	0	1	1	1	1	0			1	2	0	1	0
				,		ider 1			0	2	0			1	2	0	2	0	0	1	1	1	0			1	1	0	1	0
South Vanc Island	ouve	er		•		it Re ider 1			6	2	3 2			3	6 6	2	5 5	5 5	3 4	5 5	1 2	5 5	1 1		3	3	2	4	3	10 8
	0.			,					-	1	2			,	U	3	5	3	4	3	2	3	1		,	4	3	3	3	O
Indicator 4:	1					10n a				ı			. 1																	
		sland 12				'11		emal '13		' 15	' 11		Iale	'1 <i>1</i>	' 15	' 11		0 ye:		' 15		30–39 12			15			49 y	ears '14	' 15
Stage 0	0	6	5	3	2	0	0	0	0	0	0	6	5	3	2	0	2	2	1	1	0	2	1	1	0	0	2	1	0	0
Stage 1	4	6	3	0	3		1	1	0	1	3	5	2	0	2	0	1	2	0	2	2	1	0	0	0	2	4	1	0	0
Stage 2a	2	1	4	3	1	0	0	1	0	0	2	1	3	3	1	1	0	0	0	0	0	0	2	0	0	1	1	2	1	0
Stage 2b	3	2	6	3	5	0	0	0	3	0	3	2	6	0	5	0	0	0	0	0	0	1	1	1	1	1	1	4	1	2
Stage 3	6	5	7	4	0	4	0	1	1	0	2	5	6	3	0	1	1	1	0	0	0	1	1	0	0	2	0	1	4	0
Unknown	4	4	5	13	11	1	0	1	4	4	3	4	4	9	7	0	1	0	2	2	2	1	1	3	5	2	0	1	2	2
Total	19	24	30	26	22	5	1	4	8	5	13	23	26	18	17	2	5	5	3	5	4	6	6	5	6	8	8	10	8	4
		≥ 50) ve	ars			N	ИSМ	ſ			Ρſ	NID			1	Hete	rose	x11a		Ot	her I	Expo	siire	.	N	IR/I	Inkı	nown	1
	' 11	'12			'15	' 11				'15	' 11			' 14	'15			'13				'12 '						'13		'15
Stage 0	0	0	1	1	1	0	5	3	1	2	0	1	1	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1	0
Stage 1	0	0	0	0	1	2	4	2	0	1	1	1	1	0	0	1	1	0	0	0	0	0	0	0	1	0	0	0	0	1
Stage 2a	0	0	0	2	1	1	1	3	2	0	0	0	1	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stage 2b	2	0	1	1	2	0	0	4	0	3	3	1	2	2	2	0	1	0	1	0	0	0	0	0	0	0	0	0	0	0
Stage 3	3	3	4	0	0		3	1	1	0	5	2	4	1	0	1	0	0	1	0	0	0	0	0	0	0	0	2	1	0
Unknown	0	2	3	6	2		2	1	7	3	0	0	3	5	4	1	1	1	1	2	0	1	0	0	0	0	0	0	0	2
Total	5	5	9	10	7	6	15	14	11	9	9	5	12	10	7	4	3	1	3	2	0	1	1	0	1	0	0	2	2	3
Indicator 5	. ur	V Ca	scar	de o	f Ca	ıre		D	IAGN	NOSE	D		LIN	IKEI)	R	ETA	INEI)		ON .	ART		ADI	IEDI	ENT		SUPP	RESS	SED
marcator 3	, III		ocu,	uc o																				ADI	ILKI	DIA I				
Island Hea		· 0u	.ocu	uc o						101	8			989				895				844		ADI		778		3011		521
	lth	< 30		uc o							8				9				5					АДТ				,,,,,,	6	521 15
Island Hea	lth		ı								7			98	9			895	5			844		АДІ		778		3011	6	
Island Hea	lth ory	< 30 30-3 40-4	39 19							4 10 25	7 5 5 2			989 38 102 248	9 8 2 8			895	5 0 4			844 28 88 212		ADI		778 20 72 192		3011	1	15 52 152
Island Hea Age Catego	lth ory	< 30 30-3 40-4 ≥ 50	39 19	uc o						4 10 25 61	.7 .5 .2 .3			989 38 102 248 60	9 8 2 8 1			895 30 94 226 546	5 0 4 6			844 28 88 212 516		ADI		778 20 72 192 494		3011	1	15 52 152 102
Island Hea Age Catego	lth ory	< 30 30-3 40-4	39 19	uc o	<	< 30				4 10 25 61	7 95 62 3			989 38 102 248 60 10	9 8 2 8 1			895 30 94 226 546	5 0 4 6 6			844 28 88 212 516 8		ADI		778 20 72 192 494 8		3011	1	15 52 152 402 5
Age Catego Age Catego and MSM	lth ory	< 30 30-3 40-4 ≥ 50	39 19		< 3	< 30 30–3	-			4 10 25 61 1	27 25 32 3 2			989 33 102 243 600 102	9 8 2 8 1 0 3			895 30 94 226 546 9	5 0 4 6 6 6 9			844 28 88 212 516 8 20		ADI		778 20 72 192 494 8 17		3011	1	15 52 152 402 5
Island Hea Age Catego	lth ory	< 30 30-3 40-4 ≥ 50	39 19		3	< 30 30–3 40–4	-			4 10 25 61 1 2 4	67 05 62 3 2 44			989 36 100 246 600 10 23 44	9 8 2 8 1 0 3 4			895 30 94 226 546 9	5 0 4 6 6 6 9			844 28 88 212 516 8 20 35		ADI		778 20 72 192 494 8 17 32		3011	1 4	15 52 152 402 5 14 26
Age Catego Age Catego and MSM	lth ory ory	< 30 30-3 40-4 ≥ 50 MSN	39 19 M		3 4	< 30 30–3 40–4 ≥ 50	-			4 10 25 61 1 2 4 19	27 25 3 2 2 4 4 6 7			989 33 102 244 60 10 22 44 193	9 8 2 8 1 0 3 4 3			895 30 94 226 546 9 21 37 185	5 0 4 6 6 9 1 7			844 28 88 212 516 8 20 35 174		ADI		778 20 72 192 494 8 17 32		3011	1 4	15 52 152 402 5 14 26 138
Age Catego Age Catego and MSM	lth ory ory	< 30 30-3 40-4 ≥ 50	39 19 M		3 4 2	< 30 30–3 40–4 ≥ 50 < 30	9			4 10 25 61 1 2 4 19	27 95 32 3 2 44 46 97 8			989 36 102 246 60 10 22 44 193	9 88 22 88 11 00 33 44 33 7			895 30 94 226 546 9 21 37 185	5 0 4 6 6 9 1 7 5			844 28 88 212 516 8 20 35 174		ADI		778 20 72 192 494 8 17 32 166 2		3011	1 4	15 52 152 402 5 14 26 138 2
Age Catego Age Catego and MSM	lth ory ory	< 30 30-3 40-4 ≥ 50 MSN	39 19 M		3423	< 30 30–3 40–4 ≥ 50 < 30 30–3	9			4 10 25 61 1 2 4 19	27 35 3 2 44 46 97 8			988 36 100 244 600 10 22 44 193	99 88 88 11 00 33 44 37 76			895 30 94 226 546 9 21 37 185	55 00 14 66 66 66 77 75 55 56			844 28 88 212 516 8 20 35 174 5 35		AMI		778 20 72 192 494 8 17 32 166 2		5011	1 4	15 52 152 402 5 14 26 138 2
Age Catego Age Catego and MSM	lth ory ory	< 30 30-3 40-4 ≥ 50 MSN	39 19 M		423424445678898898988989989999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 30-3 40-4 ≥ 50 < 30 30-3 40-4</td><td>9</td><td></td><td></td><td>4 10 25 61 1 2 4 19</td><td>27 25 3 2 24 46 67 8 87</td><td></td><td></td><td>988 36 100 244 600 10 4 193 30 108</td><td>99 88 82 88 11 00 33 44 33 77 66 88</td><td></td><td></td><td>895 30 944 226 546 9 21 37 185 5 5 6 102</td><td>55 00 14 16 16 17 77 75 55 56 66 22</td><td></td><td></td><td>28 88 212 516 8 20 35 174 5 35 94</td><td></td><td>AMI</td><td></td><td>778 20 72 192 494 8 17 32 1166 2 28 84</td><td></td><td>5011</td><td>1 4</td><td>15 52 152 402 5 14 26 138 2 19 64</td></l<>	< 30 30-3 40-4 ≥ 50 < 30 30-3 40-4	9			4 10 25 61 1 2 4 19	27 25 3 2 24 46 67 8 87			988 36 100 244 600 10 4 193 30 108	99 88 82 88 11 00 33 44 33 77 66 88			895 30 944 226 546 9 21 37 185 5 5 6 102	55 00 14 16 16 17 77 75 55 56 66 22			28 88 212 516 8 20 35 174 5 35 94		AMI		778 20 72 192 494 8 17 32 1166 2 28 84		5011	1 4	15 52 152 402 5 14 26 138 2 19 64
Age Catego Age Catego and MSM	llth bry bry	< 30 30-3 40-4 ≥ 50 MSN	MSMS	SM	34234223442	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50	9			44 100 255 611 12 44 199 33 100 199	77 55 52 3 2 44 66 77 88 77 99			988 30 244 600 10 22 44 193 30 100 193	99 88 82 11 00 33 44 33 77 66 88 33			895 30 94 226 546 9 21 37 185 5 6 102	5 0 14 6 6 6 6 7 7 5 5 5 5 6 6 6 9 9 1			28 88 212 516 8 20 35 174 5 35 94		AMI		778 20 72 192 494 8 17 32 166 2 28 84 155		9011	1 4	15 52 152 402 5 14 26 138 2 19 64
Age Catego Age Catego and MSM	llth bry bry	< 30 30-3 40-4 ≥ 50 MSN	MSMS	SM	< 34< 3< 4< 2< 4< 4< 6< 6< 7< 6< 7< 7< 8< 8< 9< 8< 9< 9	< 30 30-3 40-4 ≥ 50 < 30 30-3 40-4	9 9			44 100 255 611 12 44 199 33 100 199 2	77 55 62 3 2 2 4 4 66 7 8 7 9 9 5 5 7			988 33 100 244 60 10 4 193 106 193 2	9 8 8 2 2 8 8 1 1 0 0 3 3 4 4 8 8 8 1 1 1 6 6 6 8 8 8 8 8 8 1 1 1 1 1			895 30 94 226 546 9 21 37 185 36 102 180	5 0 14 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5			844 28 88 212 516 8 20 35 174 5 35 94 167		AMI		778 20 72 192 494 8 17 32 166 2 28 84 155		9611	1 4 4	15 52 152 402 5 14 26 138 2 19 64
Age Catego Age Catego and MSM	llth bry bry	< 30 30-3 40-4 ≥ 50 MSN	MSMS	SM	342434444566788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30</td><td>9 9</td><td></td><td></td><td>44 100 255 611 12 44 199 33 100 199 2</td><td>77 155 122 33 224 4466 7788 7799 155 7755</td><td></td><td></td><td>988 30 244 600 10 22 44 193 30 100 193</td><td>9 8 8 2 2 8 8 1 1 0 3 3 4 4 3 3 7 7 6 6 8 8 1 1 1 1 1 2 2 2</td><td></td><td></td><td>895 30 94 226 546 9 21 37 185 5 6 102</td><td>5 0 1 4 6 6 6 6 7 7 7 5 5 6 6 6 6 7 7 7 7 7 7 7</td><td></td><td></td><td>28 88 212 516 8 20 35 174 5 35 94</td><td></td><td>ADI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155</td><td></td><td>9611</td><td>1 4 4</td><td>15 52 152 402 5 14 26 138 2 19 64 24 8</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30	9 9			44 100 255 611 12 44 199 33 100 199 2	77 155 122 33 224 4466 7788 7799 155 7755			988 30 244 600 10 22 44 193 30 100 193	9 8 8 2 2 8 8 1 1 0 3 3 4 4 3 3 7 7 6 6 8 8 1 1 1 1 1 2 2 2			895 30 94 226 546 9 21 37 185 5 6 102	5 0 1 4 6 6 6 6 7 7 7 5 5 6 6 6 6 7 7 7 7 7 7 7			28 88 212 516 8 20 35 174 5 35 94		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155		9611	1 4 4	15 52 152 402 5 14 26 138 2 19 64 24 8
Age Catego Age Catego and MSM	llth bry bry	< 30 30-3 40-4 ≥ 50 MSN	MSMS	SM	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 80-3</td><td>9 9</td><td></td><td></td><td>44 100 25 61 1 1 2 4 4 19 3 3 100 19 2 4</td><td>77 95 92 3 3 2 4 4 6 6 7 8 8 7 9 9 9 9 5 7 7</td><td></td><td></td><td>988 33 102 244 60 10 22 44 193 103 103 24 44</td><td>99 88 88 88 11 00 33 44 33 77 66 88 33 11 22</td><td></td><td></td><td>895 30 94 226 546 5 21 37 185 5 102 180 15 36</td><td>5 5 6 6 6 7 7 5 5 5 6 6 9 9 1 1 7 7 5 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33</td><td></td><td>ADI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27</td><td></td><td></td><td>1 4 1</td><td>15 52 152 402 5 14 26 38 2 19 64 24 8</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 80-3	9 9			44 100 25 61 1 1 2 4 4 19 3 3 100 19 2 4	77 95 92 3 3 2 4 4 6 6 7 8 8 7 9 9 9 9 5 7 7			988 33 102 244 60 10 22 44 193 103 103 24 44	99 88 88 88 11 00 33 44 33 77 66 88 33 11 22			895 30 94 226 546 5 21 37 185 5 102 180 15 36	5 5 6 6 6 7 7 5 5 5 6 6 9 9 1 1 7 7 5 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27			1 4 1	15 52 152 402 5 14 26 38 2 19 64 24 8
Age Catego Age Catego and MSM	ory	< 30 30-3 40-4 ≥ 50 MSN	39 39 149 M	SM	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 100 255 61 1 12 4 4 19 3 3 10 19 2 4 4 9</td><td>77 155 162 13 164 166 17 18 18 17 18 18 17 19 19 15 15 17 17 17 17 17 17 17 17 17 17 17 17 17</td><td></td><td></td><td>988 30 100 248 600 10 20 44 190 100 190 24 44 95</td><td>99 88 88 11 00 33 44 33 77 66 88 33 11 22 55 44</td><td></td><td></td><td>895 30 94 226 546 9 21 37 185 5 5 102 180 15 36 87</td><td>5 5 6 6 6 7 7 5 5 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 1167 15 33 83</td><td></td><td>ADI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27</td><td></td><td></td><td>1 1 1 1</td><td>15 52 152 402 5 14 26 338 2 19 64 224 8 19</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 100 255 61 1 12 4 4 19 3 3 10 19 2 4 4 9	77 155 162 13 164 166 17 18 18 17 18 18 17 19 19 15 15 17 17 17 17 17 17 17 17 17 17 17 17 17			988 30 100 248 600 10 20 44 190 100 190 24 44 95	99 88 88 11 00 33 44 33 77 66 88 33 11 22 55 44			895 30 94 226 546 9 21 37 185 5 5 102 180 15 36 87	5 5 6 6 6 7 7 5 5 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7			844 28 88 212 516 8 20 35 174 5 35 94 1167 15 33 83		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27			1 1 1 1	15 52 152 402 5 14 26 338 2 19 64 224 8 19
Age Catego Age Catego and MSM Status	Dry	< 30 30-3 40-4 ≥ 50 MSM Non	39 149 M MS	SM	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 10 25 61 1 2 4 4 19 3 10 19 2 4 4 9 9 22</td><td>7 55 62 3 2 44 66 7 8 8 7 9 9 5 7 7 2 8</td><td></td><td></td><td>988 3102 244 600 10 22 44 192 30 193 2 42 93 214</td><td>9 88 82 88 11 00 33 44 33 7 66 88 83 11 22 55 44 7</td><td></td><td></td><td>895 30 94 226 546 5 21 37 185 5 36 102 180 87 181</td><td>5 5 6 6 6 7 7 5 5 5 6 7 7 1 1</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175</td><td></td><td>ADI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76</td><td></td><td></td><td>1 1 1 1 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6</td><td>15 52 52 402 5 14 26 338 2 19 64 224 8 19 62 40</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 10 25 61 1 2 4 4 19 3 10 19 2 4 4 9 9 22	7 55 62 3 2 44 66 7 8 8 7 9 9 5 7 7 2 8			988 3102 244 600 10 22 44 192 30 193 2 42 93 214	9 88 82 88 11 00 33 44 33 7 66 88 83 11 22 55 44 7			895 30 94 226 546 5 21 37 185 5 36 102 180 87 181	5 5 6 6 6 7 7 5 5 5 6 7 7 1 1			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76			1 1 1 1 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6	15 52 52 402 5 14 26 338 2 19 64 224 8 19 62 40
Age Categorand MSM Status Gender Injection	ory	< 30 30-3 40-4 ≥ 50 MSM Non	now	SM	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 10 25 61 1 12 4 4 19 3 10 19 2 4 4 9 2 2 2 8 1</td><td>7 95 62 3 2 2 4 4 66 7 8 7 9 9 9 5 7 7 2 8 7 7 2 8 8 7 7 7 2 8 8 7 7 7 7 7</td><td></td><td></td><td>988 3102 244 600 10 22 44 193 20 42 42 47 99 214 793</td><td>9 8 8 2 2 8 8 1 1 0 3 3 4 4 3 3 7 6 6 8 8 3 1 1 1 2 2 2 2 2 4 4 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>895 30 94 226 546 51 185 102 180 15 36 87 181 724</td><td>5 5 5 6 6 6 7 7 5 5 6 6 7 7 1 1 1 1 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686</td><td></td><td>ADI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636</td><td></td><td></td><td>1 1 1 1 5 5 1 1</td><td>15 52 152 1602 5 114 226 338 2 19 64 424 8 19 62 440 503</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 10 25 61 1 12 4 4 19 3 10 19 2 4 4 9 2 2 2 8 1	7 95 62 3 2 2 4 4 66 7 8 7 9 9 9 5 7 7 2 8 7 7 2 8 8 7 7 7 2 8 8 7 7 7 7 7			988 3102 244 600 10 22 44 193 20 42 42 47 99 214 793	9 8 8 2 2 8 8 1 1 0 3 3 4 4 3 3 7 6 6 8 8 3 1 1 1 2 2 2 2 2 4 4 7 7 7 7 7 7 7 7 7 7 7 7 7			895 30 94 226 546 51 185 102 180 15 36 87 181 724	5 5 5 6 6 6 7 7 5 5 6 6 7 7 1 1 1 1 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636			1 1 1 1 5 5 1 1	15 52 152 1602 5 114 226 338 2 19 64 424 8 19 62 440 503
Age Categorand MSM Status	ory	< 30 30-3 40-4 ≥ 50 MSM Non Unk	now	SM	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 100 255 611 12 44 199 22 44 99 222 811</td><td>77 95 62 3 2 2 4 4 66 9 9 9 9 7 7 7 7 7 2 8 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>988 3102 244 600 10 22 44 193 2 41 99 214 799 192</td><td>9 8 8 2 8 8 1 1 0 3 3 4 4 3 3 7 6 6 8 8 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>895 30 94 226 546 51 37 185 5 36 102 180 187 181 181 172 172</td><td>5 5 6 6 6 7 7 5 5 6 6 7 7 1 1 1 1 2 2 2 2 2 2 2 2 3 4 4 4 4 4 4 5 6 6 6 6 7 7 7 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158</td><td></td><td>ADI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142</td><td></td><td></td><td>1 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td>15 52 52 52 402 5 14 26 38 2 19 64 224 8 19 62 40 603 118</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 100 255 611 12 44 199 22 44 99 222 811	77 95 62 3 2 2 4 4 66 9 9 9 9 7 7 7 7 7 2 8 7 7 7 7 7 7 7 7 7 7 7 7 7			988 3102 244 600 10 22 44 193 2 41 99 214 799 192	9 8 8 2 8 8 1 1 0 3 3 4 4 3 3 7 6 6 8 8 7 7 6 7 7 7 7 7 7 7 7 7 7 7 7			895 30 94 226 546 51 37 185 5 36 102 180 187 181 181 172 172	5 5 6 6 6 7 7 5 5 6 6 7 7 1 1 1 1 2 2 2 2 2 2 2 2 3 4 4 4 4 4 4 5 6 6 6 6 7 7 7 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142			1 1 1 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	15 52 52 52 402 5 14 26 38 2 19 64 224 8 19 62 40 603 118
Age Categorand MSM Status Gender Injection Drug Use	pry	< 30 30-3 40-4 ≥ 50 MSM Non Unk Male Fem PWI Non Unk	now	SM vn	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 100 255 611 12 44 199 22 44 99 222 811 199 311 500 199</td><td>27 25 22 3 2 2 4 4 6 6 7 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>988 33 100 244 600 10 22 44 190 21 47 99 214 799 300 500 186</td><td>98888888888888888888888888888888888888</td><td></td><td></td><td>895 30 94 226 546 9 21 37 185 5 36 102 180 15 36 87 181 724 463 141</td><td>5 5 6 6 7 7 5 5 6 6 7 7 1 1 1 1 2 2 2 3 3 3 4 4 4 4 5 5 5 5 6 6 7 7 7 7 7 8 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133</td><td></td><td>ABI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414</td><td></td><td></td><td>1 1 1 1 5 1 1 1 3 3</td><td>15 52 402 5 14 226 438 2 19 64 424 8 19 62 440 603 118 776</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 100 255 611 12 44 199 22 44 99 222 811 199 311 500 199	27 25 22 3 2 2 4 4 6 6 7 7 8 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7			988 33 100 244 600 10 22 44 190 21 47 99 214 799 300 500 186	98888888888888888888888888888888888888			895 30 94 226 546 9 21 37 185 5 36 102 180 15 36 87 181 724 463 141	5 5 6 6 7 7 5 5 6 6 7 7 1 1 1 1 2 2 2 3 3 3 4 4 4 4 5 5 5 5 6 6 7 7 7 7 7 8 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8 8			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133		ABI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414			1 1 1 1 5 1 1 1 3 3	15 52 402 5 14 226 438 2 19 64 424 8 19 62 440 603 118 776
Age Categorand MSM Status Gender Injection	bry	< 30 30-3 40-4 ≥ 50 MSM Non Unk Make Fem PWI Non Unk MSM	now	SM wn	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 100 255 611 12 44 199 224 811 199 311 500 199 27</td><td>77 95 95 92 3 3 2 4 4 6 6 7 7 8 8 7 7 9 9 9 5 5 7 7 7 7 7 7 7 7 7 7 7 7 7</td><td></td><td></td><td>988 3100 244 600 10 22 44 199 21 47 99 21 799 190 300 500 180 27</td><td>988888888110003334433377668883331122288000011</td><td></td><td></td><td>895 30 94 226 546 9 21 37 185 5 36 102 180 17 24 463 141 252</td><td>5 5 6 6 7 7 5 5 6 6 7 7 1 1 1 2 2 2 2 3 3 1 1 2 2 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237</td><td></td><td>ABI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223</td><td></td><td></td><td>1 1 1 1 1 5 1 1 1 3 3 1 1</td><td>15 52 152 102 5 14 226 138 2 19 64 124 8 19 62 40 603 118 176 1554 91 83</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 100 255 611 12 44 199 224 811 199 311 500 199 27	77 95 95 92 3 3 2 4 4 6 6 7 7 8 8 7 7 9 9 9 5 5 7 7 7 7 7 7 7 7 7 7 7 7 7			988 3100 244 600 10 22 44 199 21 47 99 21 799 190 300 500 180 27	988888888110003334433377668883331122288000011			895 30 94 226 546 9 21 37 185 5 36 102 180 17 24 463 141 252	5 5 6 6 7 7 5 5 6 6 7 7 1 1 1 2 2 2 2 3 3 1 1 2 2 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237		ABI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223			1 1 1 1 1 5 1 1 1 3 3 1 1	15 52 152 102 5 14 226 138 2 19 64 124 8 19 62 40 603 118 176 1554 91 83
Age Categorand MSM Status Gender Injection Drug Use	Dry	< 30 30-3 40-4 ≥ 50 MSM Non Unk MsM Non	now e ale ID -PW now M	SSM vn VID vn	342342344456788989898999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999999<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4</td><td>9 9</td><td></td><td></td><td>44 10 25 61 1 1 2 4 4 9 2 2 2 81 1 19 3 10 19 2 2 4 4 19 19 19 19 19 19 19 19 19 19 19 19 19</td><td>7 95 95 92 3 2 4 4 6 6 9 7 7 8 8 7 7 9 9 9 9 9 9 9 9 9 9 9 9 9</td><td></td><td></td><td>988 3100 244 600 10 22 44 193 103 103 103 109 24 47 99 21 799 199 308 500 186 27 34 36 36 36 36 36 36 36 36 36 36</td><td>98888881100 33 44 33 37 76688 88 11 12 2 2 5 5 14 17 7 2 2 8 8 10 10 16 16 16 16 16 16 16 16 16 16 16 16 16</td><td></td><td></td><td>895 30 94 226 546 51 185 102 186 15 36 87 181 724 463 141 252 324</td><td>5 5 5 6 6 6 7 7 5 5 5 6 6 7 1 1 1 1 2 2 2 2 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237 301</td><td></td><td>ABI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223 269</td><td></td><td></td><td>1 1 1 1 1 5 1 1 1 3 3 1 1 2 2</td><td>15 52 402 5 14 26 338 2 19 64 24 8 19 62 40 503 118 76 654 91 83 209</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 40-4 10-4	9 9			44 10 25 61 1 1 2 4 4 9 2 2 2 81 1 19 3 10 19 2 2 4 4 19 19 19 19 19 19 19 19 19 19 19 19 19	7 95 95 92 3 2 4 4 6 6 9 7 7 8 8 7 7 9 9 9 9 9 9 9 9 9 9 9 9 9			988 3100 244 600 10 22 44 193 103 103 103 109 24 47 99 21 799 199 308 500 186 27 34 36 36 36 36 36 36 36 36 36 36	98888881100 33 44 33 37 76688 88 11 12 2 2 5 5 14 17 7 2 2 8 8 10 10 16 16 16 16 16 16 16 16 16 16 16 16 16			895 30 94 226 546 51 185 102 186 15 36 87 181 724 463 141 252 324	5 5 5 6 6 6 7 7 5 5 5 6 6 7 1 1 1 1 2 2 2 2 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237 301		ABI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223 269			1 1 1 1 1 5 1 1 1 3 3 1 1 2 2	15 52 402 5 14 26 338 2 19 64 24 8 19 62 40 503 118 76 654 91 83 209
Age Categorand MSM Status Gender Injection Drug Use MSM Statu	ory	< 30 30-3 40-4 ≥ 50 MSM Non Unk MSM Non Unk Non Unk	now e ale ID -PW I -MS now I -MS	SSM vvn VID vvn SSM vvn	342342344545678911111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111111<l< td=""><td>< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50</td><td>999999</td><td></td><td></td><td>44 19 3 10 19 22 44 9 22 81 19 31 50 19 27 34 39</td><td>7 15 12 13 14 16 17 18 17 18 17 17 18 19 19 19 19 19 19 19 19 19 19 19 19 19</td><td></td><td></td><td>988 36 100 244 600 10 224 44 199 214 799 192 303 500 180 271 344 372 344 372</td><td>9 8 8 8 1 1 0 0 3 3 4 4 3 3 7 6 8 8 3 3 1 1 2 2 5 5 4 4 7 7 7 7 7 8 8 8 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1</td><td></td><td></td><td>895 30 94 226 546 51 85 36 102 180 15 36 87 181 724 463 141 252 324 320</td><td>5 5 6 6 7 7 5 5 5 6 7 1 1 4 2 2 2 3 3 1 1 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4</td><td></td><td></td><td>844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237 301 306</td><td></td><td>ABI</td><td></td><td>778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223 269 286</td><td></td><td></td><td>1 1 1 1 5 1 1 1 3 3 2 2 2</td><td>15 52 402 5 14 26 338 2 19 64 224 8 19 62 40 503 118 76 83 91 83 92 92 92</td></l<>	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50	999999			44 19 3 10 19 22 44 9 22 81 19 31 50 19 27 34 39	7 15 12 13 14 16 17 18 17 18 17 17 18 19 19 19 19 19 19 19 19 19 19 19 19 19			988 36 100 244 600 10 224 44 199 214 799 192 303 500 180 271 344 372 344 372	9 8 8 8 1 1 0 0 3 3 4 4 3 3 7 6 8 8 3 3 1 1 2 2 5 5 4 4 7 7 7 7 7 8 8 8 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			895 30 94 226 546 51 85 36 102 180 15 36 87 181 724 463 141 252 324 320	5 5 6 6 7 7 5 5 5 6 7 1 1 4 2 2 2 3 3 1 1 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237 301 306		ABI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223 269 286			1 1 1 1 5 1 1 1 3 3 2 2 2	15 52 402 5 14 26 338 2 19 64 224 8 19 62 40 503 118 76 83 91 83 92 92 92
Age Categorand MSM Status Gender Injection Drug Use MSM Statu	ory	< 30 30-3 40-4 ≥ 50 MSM Non Unk MSM Non Unk Cent	e ale ID -PW now M -MS	SM vn SM vn Van	3 3 4 2 2 3 3 4 4 2 2 2 2 2 2 2 2 2 2 2	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50	9 9 9 9 9	1		44 100 255 61 1 12 4 4 19 22 81 119 31 50 19 27 34 39 27	27 25 22 3 2 4 4 6 7 7 8 7 7 9 9 9 9 9 9 8 8 8 9 9 9 9 9 9			988 36 100 244 600 10 224 44 193 214 799 303 500 188 277 344 372 263	9 8 8 8 8 1 1 0 3 3 4 4 3 3 7 6 6 8 8 3 3 1 1 2 2 2 5 5 1 1 1 1 2 1 2 1 1 1 1 1 1			895 30 94 226 546 37 185 5 36 102 180 15 36 87 181 724 172 292 463 141 252 324 320 241	5 5 5 6 6 7 7 5 5 5 6 6 7 1 1 1 2 2 2 2 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 2275 436 133 237 301 306 229		ABI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 1173 636 1142 2242 414 122 223 269 286 208			1 1 1 1 5 5 1 1 1 3 3 2 2 2 1 1	15 52 402 5 14 26 338 2 19 64 224 8 19 62 440 603 118 776 354 91 83 209 229 78
Age Categorand MSM Status Gender Injection Drug Use MSM Statu	ory ory	< 30 30-3 40-4 ≥ 50 MSM Non Unk MSM Non Unk Non Unk	now e ale iD -PW now f -MS now tral	VID vn SM vn Van	couve	< 30 80-3 40-4 ≥ 50 < 30 80-3 40-4 ≥ 50 × 30 80-3 40-4 ≥ 50 ver Islanda	9 9 9 9 9 9	1		44 19 3 10 19 22 44 9 22 81 19 31 50 19 27 34 39	27 25 22 3 2 4 4 6 6 7 8 7 7 9 9 5 7 7 7 2 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9			988 36 100 244 600 10 224 44 199 214 799 192 303 500 180 271 344 372 344 372	9 8 8 8 1 1 0 3 3 4 4 3 3 7 6 6 8 8 3 3 1 1 2 2 5 5 1 1 1 1 1 2 1 1 1 1 1 1 1 1			895 30 94 226 546 51 85 36 102 180 15 36 87 181 724 463 141 252 324 320	5 5 6 6 7 7 5 5 5 6 6 7 1 1 1 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1			844 28 88 212 516 8 20 35 174 5 35 94 167 15 33 83 175 686 158 275 436 133 237 301 306		ADI		778 20 72 192 494 8 17 32 166 2 28 84 155 10 27 76 173 636 142 242 414 122 223 269 286			1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	15 52 402 5 14 26 338 2 19 64 224 8 19 62 40 503 118 76 83 91 83 92 92 92

33 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q1 Q3 Q4 Q1 Q4 Q3 Q4 Q1 Q4 Q3 Q4 Q1 Q4 Q4 Q4 Q4 Q4 Q4	Indicator 6: Programn	natic Complia		re (PCS)								
3 CJ DT Tests 82,0% 78,2% 60,93% 60,4% 66,7% 75,6% 78,9% 78,3% 15,8% 13,3% 15,6% 12,2% 12,6% 15,8% 13,3% 15,6% 13,2% 15,8% 13,3% 15,6% 13,2% 15,8% 13,9% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 2,0% 3,0% 38,9% 32,5% 2,6% 3,6% 36,5% 33,5% 37,8% 36,5% 36,5% 36,5% 34,0% 38,3% 37,8% 36,5% 36,6% 7,0% <			2014 O3	O4		2015 O1	O2	O3	(04	2016 O1	Q2
3 Viral Load Tests 4.0% 5.5% 11.3% 12.2% 13.3% 15.6% 13.2% 15.6% 2.2% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 2.6% 3.95% 3.55% 3.55% 3.6% 3.4% 3.4% 2.6% 2.6% 3.95% 3.55% 3.5%	< 3 CD4 Tests				6							
No Baseline Genotype 2.0% 1.8% 1.9% 2.0% 2.0% 0.0% 2.2% 2.6% 2.6% 3.0% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9% 3.9												15.8%
Baseline CD4 < 200 cells/µL 20.9% 20.9% 18.9% 22.4% 26.7% 26.7% 30.5% 39.5% 39.0% 30.0% 18.0% Recommended ART 12.49% 10.9% 7.5% 4.1% 2.2% 4.4% 7.9% 7.9% 7.9% Non Viral suppression at 9 Mo. 38.0% 36.4% 34.0% 38.8% 37.8% 37.8% 36.8% 36.89 PCS Score: 0 5 6 9 9 9 11 10 0 5 PCS Score: 1 15 18 18 14 12 12 9 7 7 PCS Score: 2 26 27 20 19 13 15 18 18 14 PCS Score: 2 26 27 20 19 13 15 18 18 PCS Score: 2 26 27 20 19 13 15 18 10 PCS Score: 4 Ornor 0 0 0 0 0 0 1 1 1 1 1 10 10 10 10 10 10												
Non-Recommended ART 12.0% 10.9% 7.5% 4.1% 2.2% 4.4% 7.9% 7.9% 7.0% 38.8% 36.8%	, ,	lle/uI										
Non Viral suppression at 9 Mo. 38.0% 36.4% 34.0% 38.8% 37.8% 37.8% 36.89 36.89 PCS Score: 0 5 6 9 9 9 11 10 5 5 1 PCS Score: 1 15 18 18 14 12 12 9 7 7 1 PCS Score: 2 26 27 20 19 13 15 18 18 PCS Score: 3 1		•										
PCS Scores 0 5 6 9 9 9 11 10 5												
PCS Score: 2 26 27 20 19 13 15 18 18		at 9 IVIO.			3							
PCS Score: 2 26 27 20 19 13 15 18 18 PCS Score: 3 4 4 6 7 8 10 7 7 10 10 1 1 1 1 1 1 1 1 1 1 1 1 1												
PCS Score: 4 or more 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1												
PCS Score: 4 or more												
Total (n=) 50 55 53 49 45 45 38 38 36 18 18 18 18 18 18 18 18 18 18 19 19 22 16 11 14 29 18 18 19 19 22 16 11 14 29 18 18 19 19 29 18 19 19 19 19 19 19 19 19 19 19 19 19 19												
Indicator 7: New DTP ARV Participants First Starts 8 12 8 11 6 9 4 1.1 Experienced Starts 20 15 19 22 16 11 14 22 Indicator 8: CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants CD4 ≥ 500 0 4 1 3 3 1 1												1
Eirst Starts 8 12 8 11 6 9 4 11 Experienced Starts 20 15 15 12 22 16 11 14 22 Experienced Starts 8: CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants CD4 ≥500 0 1 1 2 3 1 1 1 - CD4 2500 1 1 1 1 1 2 1 2 1 2 - CD4 2500 3 2 2 0 1 1 1 3 3 - CD4 2500 3 3 2 0 1 1 1 3 3 - CD4 2500 3 3 2 0 1 1 1 3 3 - CD4 2500 3 3 2 0 1 1 1 3 3 - CD4 2500 3 3 2 0 0 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 3 3 - CD4 2501 3 2 0 0 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 1 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 - CD4 2501 3 3 2 0 0 1 1 1 2 3 3 3 836 847 86 Entactive DTP Participants 786 800 811 820 833 836 847 86 Entactive DTP Participants 110 110 115 117 121 128 128 126 122 Indicator 10: Antiretroviral Adherence 2 95% 11 9 8 5 11 8 6 1 1 80% to < 95% 2 2 2 2 2 6 3 3 3 2 2 Entactive DTP Participants 110 1 10 110 115 117 121 128 128 126 12 Indicator 11: Resistance Testing and Results Suppressed 512 459 562 509 480 490 541 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 74 65 68 81 73 61 55 Wild Type 59 754 648 602 588 575 620 620 Enclass 1 0 0 2 3 3 2 2 0 18 6 7 10 13 11 Enclass 1 1 0 2 4 3 2 2 3 1 1 0 10 Enclass 1 1 0 2 4 3 2 2 3 1 1 0 0 10 Enclass 1 1 0 2 4 4 3 2 2 3 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Total (n=)		50	55		53	49	45	•	45	38	38
Experienced Starts 20 15 19 22 16 11 14 22 Indicator 8: CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants CD4 ≥ 500 0 4 1 1 3 1 1	Indicator 7: New DTP	ARV Particip	ants									
Indicator 8: CD4 Cell Count at ART Initiation for ARV-Naïve DTP Participants CD4 ≥500 0 4 1 2 2 0 0 1 1 1 - CD4 ≥500 1 1 1 - CD4 ≥500 1 1 1 1 - CD4 ≥50 1 2 1 2 PO ≥500 ≥ CD4 ≥50-199 1 2 1 1 4 3 3 2 0 0 - CD4 ≥50-199 2 1 1 4 3 3 2 0 0 - PO ≥500 2 2 0 1 1 1 3 3 - CD4 ≥50 3 2 2 0 1 1 1 3 3 - CD4 ≥50 1 2 200 2 235 ≥230 - PO ≥50 1 1 1 1 2 1 2 2 1 2 1 2 1 2 1 2 1 2 1	First Starts											12
CD4 ≥ 500	Experienced Starts		20	15		19	22	16		11	14	20
CD4 ≥ 500	Indicator 8: CD4 Cell	Count at ART	Initiati	on for ARV	-Naïve	DTP Parti	icipants					
CD4 350-499	CD4 ≥ 500							1		1	-	-
CD4 50−199	CD4 350-499		1	2		2	0	1		1	_	-
CD4 50−199	CD4 200-349		1	1		1	2	1		2	_	_
CD4 < 50						4					_	_
Total (n=)											_	_
Total (n=) 7 10 8 9 6 7 ≤ 5 ≤ 1 Indicator 9: Active and Inactive DTP Participants Active DTP Participants 786 800 811 820 833 836 847 866 801 120 110 115 117 121 128 126 122 124 128 126 122 149 128 126 122 149 129 129 129 129 129 129 129 129 129 12						-			2		_	_
Indicator 9: Active and Inactive DTP Participants Active DTP Participants 786 800 811 820 833 836 847 866 810 811 820 833 836 847 866 810 811 820 833 836 847 866 810 811 820 833 836 847 866 810 811 820 813 836 847 866 812 812 812 812 812 812 812 812 812 812	•								2.		≤ 5	≤ 5
Active DTP Participants 786 800 811 820 833 836 847 86 861 finactive DTP Participants 110 110 115 117 121 128 126 125 126 127 127 128 126 127 128 126 127 128 126 127 128 126 127 128 126 127 128 128 126 127 128 128 126 127 128 128 126 127 128 128 126 127 128 128 126 127 128 128 128 128 128 128 128 128 128 128												
Indicator 10: Antiretroviral Adherence ≥ 95% 11 9 8 5 11 8 6 1 80% to < 95% 2 2 2 2 6 3 3 3 2 2 40% to < 80% 1 1 3 3 3 1 1 1 1 Total (n=) 14 12 13 14 15 12 10 10 Indicator 11: Resistance Testing and Results Suppressed 512 459 562 509 480 490 541 55 Wild Type 59 74 65 68 81 73 61 56 Never Genotyped 7 6 6 6 6 10 3 7 6 Percentage 1 1 2 4 3 2 3 2 3 1 6 Percentage 2 4 3 2 3 1 6 Percentage 3 1 2 4 3 3 2 3 1 6 Percentage 3 1 3 5 10 16 Percentage 4 3 2 3 1 6 Percentage 5 1 3 9 13 13 5 10 16 Percentage 5 1 2 4 3 3 2 3 1 6 Percentage 6 1 3 3 1 6 Percentage 6 1 3 3 7 6 Percentage 6 1 3 3 1 7 7 6 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Percentage 7 1 1 1 1 1 1 1 1 Perc						044	000	000		2 -	0.45	0.4
Indicator 10: Antiretroviral Adherence ≥ 95% 11 9 8 5 11 8 6 1 80% to < 95% 2 2 2 2 6 3 3 3 2 3 40% to < 80% 1 1 1 3 3 3 1 1 1 1 1 Total (n=) 14 12 13 14 15 12 10 10 Indicator 11: Resistance Testing and Results Suppressed 512 459 562 509 480 490 541 556 Never Genotyped 59 74 65 68 81 73 61 56 Never Genotyped 7 6 6 6 6 10 3 7 61 1-Class 15 13 9 13 13 5 10 16 1-Class 15 13 9 13 13 5 10 16 1-Class 1 2 4 4 3 2 3 1 1 6 1-Class 1 5 13 9 13 13 5 10 16 Total (n=) 595 554 648 602 588 575 620 62 Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 201. CD4 < 200 at Cases 23 22 20 18 6 7 10 13 1. ART initiation Rate per 100,000 3.2 3.0 2.7 2.4 0.8 0.9 1.3 1.7 1. AIDS Cases Cases 11 6 12 15 11 8 7 7 5 5 (DTP Reports) Rate per 100,000 1.5 0.8 1.6 2.0 1.5 1.1 0.9 0.9 0.4 AIDS Cases Cases 12 12 12 16 18 12 11 7 ≤ 5 (BCCDC Reports) Rate per 100,000 1.7 1.6 2.2 2.4 1.6 1.5 0.9 0.7 Indicator 13: HIV-Related Mortality 2004 2005 2006 2007 2008 2009 2010 2010 2011 17 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84												
≥ 95% 11 9 8 5 11 8 6 1 80% to < 95% 2 2 2 2 2 6 6 3 3 3 2 2 3 40% to < 80% 1 1 1 3 3 3 1 1 1 1 1 1 <	Inactive DTP Participa	ints	110	110		115	117	121	13	28	126	127
80% to < 95%	Indicator 10: Antiretro	oviral Adhere	nce									
80% to < 95%	≥ 95%		11	9		8	5	11		8	6	11
40% to < 80%	80% to < 95%		2			2	6	3		3	2	3
< 40% 0 0 0 0 0 0 0 1 Total (n=) 14 12 13 14 15 12 10 10 Indicator 11: Resistance Testing and Results Suppressed Suppressed 512 459 562 509 480 490 541 556 Wild Type 59 74 65 68 81 73 61 56 Never Genotyped 7 6 6 6 6 10 3 7 4 1-Class 15 13 9 13 13 5 10 10 2-Class 1 2 4 3 2 3 1 0 2-Class 1 0 2 3 2 3 1 0 3-Class 1 0 2 3 2 0 0 0 Total (n=) 595 554 648 602 588 575 620 620 Indicator 12: AIDS-Defining												1
Total (n=) 14 12 13 14 15 12 10 10 Indicator 11: Resistance Testing and Results Suppressed 512 459 562 509 480 490 541 556 Wild Type 59 74 65 68 81 73 61 560 Never Genotyped 7 6 6 6 6 10 3 7 7 4 1-Class 15 13 9 13 13 5 10 11 2-Class 1 2 4 33 2 3 1 1 0 2-Class 1 0 2 4 3 2 3 1 1 0 2-Class 1 0 2 4 3 2 3 1 1 0 3-Class 1 0 2 559 554 648 602 588 575 620 620 Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 2013 CD4 < 200 at Cases 23 22 20 18 6 7 10 13 1. AIDS Cases Cases 11 6 12 15 11 8 7 7 5 ≤ 10 (DTP Reports) Rate per 100,000 1.5 0.8 1.6 2.0 1.5 1.1 0.9 0.9 0.9 AIDS Cases Cases 12 12 12 16 18 12 11 7 ≤ 5 (BCCDC Reports) Rate per 100,000 1.7 1.6 2.2 2.4 1.6 1.5 0.9 0.7 Indicator 13: HIV-Related Mortality 2004 2005 2006 2007 2008 2009 2010 2011 2012 2011 Island Health 16 18 22 18 17 11 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84												1
Suppressed 512 459 562 509 480 490 541 550												16
Suppressed 512 459 562 509 480 490 541 558 Wild Type 59 74 65 68 81 73 61 56 Never Genotyped 7 6 6 6 10 3 7 4 1-Class 15 13 9 13 13 5 10 10 2-Class 1 2 4 3 2 3 1 0 3-Class 1 0 2 3 2 0 0 0 3-Class 1 0 2 3 2 0 0 0 Total (n=) 595 554 648 602 588 575 620 620 Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 201 CD4 < 200 at												
Wild Type 59 74 65 68 81 73 61 56 Never Genotyped 7 6 6 6 6 10 3 7 6 1-Class 15 13 9 13 13 5 10 10 2-Class 1 2 4 3 2 3 1 0 3-Class 1 0 2 3 2 0 0 0 3-Class 1 0 2 3 2 0 0 0 3-Class 1 0 2 3 2 0 0 0 3-Class 1 0 2 3 2 0 0 0 0 Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 2015 CD4 < 200 at		e Testing and				562	500	400	44	20	F 4.1	550
Never Genotyped 7 6 6 6 6 10 3 7 7 4 1 1 1 7 14 1 1 7 14 1 1 1 7 1 14 Per 100 HIV+ Population 1 1 10 10 10 10 10 10 10 10 10 10 10 10												
1-Class 15 13 9 13 13 5 10 10 20-10 10 10 10 10 10 10 10 10 10 10 10 10 1												
2-Class 1 2 4 3 2 3 1 0 0 3 6 6 6 6 7 6 6 6 6 6 7 1 0 1 3 1 0 0 6 6 6 6 7 1 0 1 3 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	• •											4
3-Class 1 0 2 3 2 0 0 0 Total (n=) 595 554 648 602 588 575 620 620 Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 2012 CD4 < 200 at												
Indicator (n=) 595 554 648 602 588 575 620 620 Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 2012 CD4 < 200 at												C
Indicator 12: AIDS-Defining Illness 2007 2008 2009 2010 2011 2012 2013 2014 2012 CD4 < 200 at												C
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Total (n=)		595	554		648	602	588	57	75	620	620
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Indicator 12: AIDS-De	efining Illness	3	2007	2008	2009	2010	2011	2012	2013	2014	2015
ART initiation $Rate\ per\ 100,000$ 3.2 3.0 2.7 2.4 0.8 0.9 1.3 1.7 1.4 AIDS Cases Cases 11 6 12 15 11 8 7 7 ≤ 1 (DTP Reports) $Rate\ per\ 100,000$ 1.5 0.8 1.6 2.0 1.5 1.1 0.9 0.9 0.9 AIDS Cases Cases 12 12 16 18 12 11 7 ≤ 5 (BCCDC Reports) $Rate\ per\ 100,000$ 1.7 1.6 2.2 2.4 1.6 1.5 0.9 0.7 Indicator 13: HIV-Related Mortality 2004 2005 2006 2007 2008 2009 2010 2011 Island Health 16 18 22 18 17 11 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84	CD4 < 200 at											14
AIDS Cases	ART initiation	Rate per 100,	000	3.2	3.0	2.7	2.4	0.8	0.9	1.3	1.7	1.8
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	AIDS Cases											≤ 5
AIDS Cases Cases 12 12 16 18 12 11 7 ≤ 5 (BCCDC Reports) Rate per 100,000 1.7 1.6 2.2 2.4 1.6 1.5 0.9 0.7 Indicator 13: HIV-Related Mortality 2004 2005 2006 2007 2008 2009 2010 2011 Island Health 16 18 22 18 17 11 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84	(DTP Reports)		000									0.4
(BCCDC Reports) Rate per 100,000 1.7 1.6 2.2 2.4 1.6 1.5 0.9 0.7 Indicator 13: HIV-Related Mortality 2004 2005 2006 2007 2008 2009 2010 2011 Island Health 16 18 22 18 17 11 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84		•										
Indicator 13: HIV-Related Mortality 2004 2005 2006 2007 2008 2009 2010 2011 Island Health 16 18 22 18 17 11 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84	(BCCDC Reports)		000									
Island Health 16 18 22 18 17 11 7 14 Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84	•	•										
Per 100 HIV+ Population 2.25 2.49 2.98 2.40 2.29 1.47 0.92 1.84		ated Mortality	у									
Per 100,000 Population 1.42 1.57 1.89 1.52 1.40 0.89 0.55 1.09	-											
	Per 100,000 Population	1		1.42	1.57	1.89	1.52	1.40	0.89	0.55	1.09	